搜尋
Telix Pharmaceuticals Ltd
TLX添加自選
10.560USD
-0.300-2.76%
收盤 05/15, 16:00（美東）報價延遲15分鐘
0.00總市值
--本益比TTM
關於 Telix Pharmaceuticals Ltd 公司
Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. It is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Its segments include Therapeutics, Precision Medicine and Telix Manufacturing Solutions. Therapeutics segment develops targeted radionuclide therapies for urologic, neurologic, musculoskeletal and hematological cancers. Precision Medicine segment focuses on bringing diagnostic imaging solutions to market. Precision Medicine segment also includes MedTech and International businesses. Telix Manufacturing Solutions segment is its global network of facilities designed to deliver patient doses worldwide. Its pipeline products include TLX591, TLX250, TLX101, TLX66, TLX592, TLX252, TLX400, Illuccix (68Ga-PSMA-11) and TLX007-CDx.
Telix Pharmaceuticals Ltd簡介
公司代碼TLX
公司名稱Telix Pharmaceuticals Ltd
上市日期Nov 15, 2017
CEOOrtiz (Raphaeel)
員工數量- -
證券類型Depository Receipt
年結日- -
公司地址55 Flemington Road
城市MELBOURNE
上市交易所NASDAQ OMX - NASDAQ BASIC
國家Australia
郵編3051
電話61390933855
網址https://telixpharma.com/
公司代碼TLX
上市日期Nov 15, 2017
CEOOrtiz (Raphaeel)
Telix Pharmaceuticals Ltd公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Christian P. Behrenbruch, J.D., Ph.D.
Dr. Christian P. Behrenbruch, J.D., Ph.D.
Group Chief Executive Officer, Managing Director, Executive Director
Group Chief Executive Officer, Managing Director, Executive Director
--
--
Dr. Mark Nelson, Ph.D.
Dr. Mark Nelson, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Jann Skinner
Ms. Jann Skinner
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. David Cade
Dr. David Cade
Group Chief Medical Officer
Group Chief Medical Officer
--
--
Mr. Richard Valeix
Mr. Richard Valeix
Group Chief Commercial Officer
Group Chief Commercial Officer
--
--
Ms. Tiffany P. Olson
Ms. Tiffany P. Olson
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Darren Smith, CPA
Mr. Darren Smith, CPA
Group Chief Financial Officer
Group Chief Financial Officer
--
--
Mr. Kevin Richardson
Mr. Kevin Richardson
Chief Executive Officer - Telix Precision Medicine
Chief Executive Officer - Telix Precision Medicine
--
--
Mr. Raphaeel Ortiz
Mr. Raphaeel Ortiz
Chief Executive Officer - Telix International
Chief Executive Officer - Telix International
--
--
Ms. Genevieve Ryan
Ms. Genevieve Ryan
Company Secretary
Company Secretary
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Christian P. Behrenbruch, J.D., Ph.D.
Dr. Christian P. Behrenbruch, J.D., Ph.D.
Group Chief Executive Officer, Managing Director, Executive Director
Group Chief Executive Officer, Managing Director, Executive Director
--
--
Dr. Mark Nelson, Ph.D.
Dr. Mark Nelson, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Jann Skinner
Ms. Jann Skinner
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. David Cade
Dr. David Cade
Group Chief Medical Officer
Group Chief Medical Officer
--
--
Mr. Richard Valeix
Mr. Richard Valeix
Group Chief Commercial Officer
Group Chief Commercial Officer
--
--
Ms. Tiffany P. Olson
Ms. Tiffany P. Olson
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
收入明細
由於公司未披露，未能獲取相關數據
由於公司未披露，未能獲取相關數據
業務
地區
由於公司未披露，未能獲取相關數據
股東統計
更新時間: 5月14日 週四
更新時間: 5月14日 週四
持股股東
股東類型
持股股東
持股股東
佔比
Portland Investment Counsel Inc.
0.08%
Lazard Asset Management, L.L.C.
0.07%
Raiffeisen Bank International AG
0.04%
Fidelity Management & Research Company LLC
0.04%
Private Advisor Group LLC
0.01%
其他
99.76%
持股股東
持股股東
佔比
Portland Investment Counsel Inc.
0.08%
Lazard Asset Management, L.L.C.
0.07%
Raiffeisen Bank International AG
0.04%
Fidelity Management & Research Company LLC
0.04%
Private Advisor Group LLC
0.01%
其他
99.76%
股東類型
持股股東
佔比
Investment Advisor
0.24%
Investment Advisor/Hedge Fund
0.09%
Research Firm
0.06%
Hedge Fund
0.03%
Bank and Trust
0.02%
其他
99.57%
機構持股
更新時間: 4月1日 週三
更新時間: 4月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2026Q1
61
1.47M
0.43%
+326.20K
2025Q4
40
845.28K
0.25%
+354.64K
2025Q3
25
456.14K
0.13%
+379.51K
2025Q2
11
269.45K
0.08%
+265.72K
2025Q1
6
20.71K
0.01%
+16.98K
2024Q4
1
3.73K
0.00%
+3.73K
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Portland Investment Counsel Inc.
266.20K
0.08%
+138.20K
+107.97%
Dec 31, 2025
Lazard Asset Management, L.L.C.
250.52K
0.07%
+135.89K
+118.56%
Dec 31, 2025
Fidelity Management & Research Company LLC
123.57K
0.04%
+5.09K
+4.30%
Dec 31, 2025
Private Advisor Group LLC
46.34K
0.01%
+4.23K
+10.05%
Dec 31, 2025
Marshall Wace LLP
46.66K
0.01%
-1.92K
-3.94%
Dec 31, 2025
JPMorgan Private Bank (United States)
44.49K
0.01%
+19.14K
+75.47%
Dec 31, 2025
Quadrature Capital LLP
36.83K
0.01%
+36.83K
--
Dec 31, 2025
Mariner Wealth Advisors
36.58K
0.01%
+36.58K
--
Dec 31, 2025
查看更多
持股ETF
機構名稱
佔比
暫無數據
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
除權除息日
類型
比率
暫無數據
公告日期
除權除息日
類型
比率
暫無數據
